BETA DRUGS LIMITED
Q1 FY27, unaudited
- Revenue
- ₹125.55 Cr
- Profit after tax
- ₹16.49 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 125.55 | — | 384.83 |
| Other income | 1.58 | — | 11.18 |
| Total income | 127.13 | — | 396.01 |
| Employee benefit expense | 20.40 | — | 68.01 |
| Finance costs | 2.56 | — | 15.31 |
| Depreciation & amortisation | 4.35 | — | 17.15 |
| Total expenses | 105.09 | — | 341.61 |
| Profit before tax | 22.04 | — | 54.39 |
| Tax expense | 5.56 | — | 12.91 |
| Profit after tax | 16.49 | — | 41.48 |
| Total comprehensive income | 16.49 | — | 41.66 |
| Earnings per share, basic | ₹14.78 | ₹40.92 |
|---|---|---|
| Earnings per share, diluted | ₹14.78 | ₹40.92 |
Q1 FY27 — unaudited, from the company’s filing with NSE. Source
FY26 — from the company’s filing with NSE. Source
Why the dash
Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.
Earnings call
BETA DRUGS LIMITED has not filed a concall transcript in the last 4 quarters.
Filings
0 shown · 0 published by the exchange
The exchange has published no filings for this company in the period Parakho holds.
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.